Moderna and OpenAI Collaborate To Advance mRNA Medicine
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Morgan Stanley Comments on Moderna (MRNA) Collaboration with OpenAI
April 24, 2024 12:31 PM EDTMorgan Stanley analyst Matthew Harrison reiterated an Equalweight rating and $89.00 price target on Moderna (NASDAQ: MRNA)
The analyst comments "MRNA announced an update regarding the company's ongoing collaboration with OpenAI (privately held) on generative AI tools, noting that the ChatGPT Enterprise is embedded across MRNA's business functions and has achieved more than 80% internal adoption throughout... More
